The Role of Small Molecule NMR in Medicinal Chemistry
Webinar Overview
Since its early days, nuclear magnetic resonance (NMR) has played an important role in the pharmaceutical industry. NMR is traditionally used by medicinal chemists for structure elucidation of both synthesized molecules and active compounds isolated from natural sources. However, it can also be a valuable tool for reaction monitoring, the characterization of solution conformations, the investigation of metabolites, hit-to-lead optimization and quantitation.
In this on-demand webinar, Kathleen Farley, Senior Principal Scientist, R&D, Pfizer Inc, describes how NMR spectroscopy is integrated into the Pfizer drug discovery pipeline and how the technique is used in a walk-up environment by medicinal chemists and NMR scientists to solve challenging drug discovery problems.
Additionally, Anna Codina, Director Pharmaceutical Business Unit, Bruker BioSpin, finishes the webinar by presenting new additions to the NMR instrumentation family that make the technique available to a wider audience, overcoming some of the current cost concerns. This expansion includes both affordable high-resolution and benchtop instrumentation.
Thursday 02 December 2021
04:00 PM CET
Speakers
Kathleen Farley
Senior Principal Scientist, R&D Pfizer IncKathleen Farley is a Senior Principal Scientist in the R&D division at Pfizer Inc with over 30 years of experience in the pharmaceutical industry providing NMR support for Medicinal Chemistry research. She has taught the American Chemical Society (ACS) NMR course, “1D and 2D NMR Spectroscopy: Structure Determination of Small Molecule Organic Compounds” with Greg Walker for the last 10 years. Kathleen also has over 40 publications including a book chapter and two patents. Her current research includes the structural characterisation of small molecules and peptides using residual dipolar couplings.
Anna Codina, Ph.D.
Senior Director Strategy and Business Development, SciY
Anna has a degree in Chemistry and a Ph.D. in Protein NMR from the University of Barcelona, Spain. She undertook her post-doc in protein NMR at the MRC Laboratory of Molecular Biology in Cambridge, UK, and following that worked in the Analytical R&D department of Pfizer for seven years, becoming proficient in low level impurity structure elucidation, reaction monitoring, qNMR and the preparation of regulatory documentation. She received a Pfizer Worldwide Achievement Award for the implementation of reaction monitoring by NMR in an open access environment.
She joined Bruker in 2011 and had different roles since including Material Characterisation Laboratory Manager, Product Portfolio Manager and for several years was in charge of driving the Biopharmaceutical business at Bruker BioSpin. Anna recently moved to SciY as Senior Director of Strategy and Business Development.